Koret School of Veterinary Medicine, The Hebrew University, Rehovot, Israel.
Department of Microbiology and Molecular Genetics, IMRIC, Hadassah Medical School, The Hebrew University, Jerusalem, Israel.
Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):403-410. doi: 10.1016/j.ijpddr.2018.08.002. Epub 2018 Aug 23.
Leishmania infantum is one of the causative agents of visceral leishmaniasis (VL), a widespread, life-threatening disease. This parasite is responsible for the majority of human VL cases in Brazil, the Middle East, China, Central Asia and the Mediterranean basin. Its main reservoir are domestic dogs which, similar to human patients, may develop severe visceral disease and die if not treated. The drug allopurinol is used for the long-term maintenance of dogs with canine leishmaniasis. Following our report of allopurinol resistance in treated relapsed dogs, we investigated the mechanisms and markers of resistance to this drug. Whole genome sequencing (WGS) of clinical resistant and susceptible strains, and laboratory induced resistant parasites, was carried out in order to detect genetic changes associated with resistance. Significant gene copy number variation (CNV) was found between resistant and susceptible isolates at several loci, including a locus on chromosome 30 containing the genes LinJ.30.3550 through LinJ.30.3580. A reduction in copy number for LinJ.30.3560, encoding the S-adenosylmethionine synthetase (METK) gene, was found in two resistant clinical isolates and four induced resistant clonal strains. Using quantitative real time PCR, this reduction in METK copy number was also found in three additional resistant clinical isolates. Furthermore, inhibition of S-adenosylmethionine synthetase encoded by the METK gene in allopurinol susceptible strains resulted in increased allopurinol resistance, confirming its role in resistance to allopurinol. In conclusion, this study identified genetic changes associated with L. infantum resistance to allopurinol and the reduction in METK copy number identified may serve as a marker for resistance in dogs, and reduced protein activity correlated with increased allopurinol resistance.
婴儿利什曼原虫是内脏利什曼病(VL)的病原体之一,这是一种广泛存在且危及生命的疾病。这种寄生虫是巴西、中东、中国、中亚和地中海盆地大多数人类内脏利什曼病病例的罪魁祸首。其主要宿主是家养狗,如果不治疗,它们与人类患者一样可能会患上严重的内脏疾病并死亡。别嘌醇是用于治疗犬利什曼病的长期维持药物。在我们报告治疗后复发的狗对别嘌醇耐药后,我们研究了对这种药物的耐药机制和标志物。对临床耐药和敏感株以及实验室诱导耐药寄生虫进行了全基因组测序(WGS),以检测与耐药相关的遗传变化。在几个基因座中发现了耐药和敏感分离株之间的显著基因拷贝数变异(CNV),包括包含基因 LinJ.30.3550 到 LinJ.30.3580 的 30 号染色体上的一个基因座。在两个耐药临床分离株和四个诱导耐药克隆株中发现 LinJ.30.3560(编码 S-腺苷甲硫氨酸合成酶(METK)基因)的拷贝数减少。使用定量实时 PCR,在另外三个耐药临床分离株中也发现了 METK 基因拷贝数减少。此外,在所有嘌醇敏感株中抑制由 METK 基因编码的 S-腺苷甲硫氨酸合成酶导致了对别嘌醇的耐药性增加,证实了其在对别嘌醇耐药中的作用。总之,本研究确定了与婴儿利什曼原虫对别嘌醇耐药相关的遗传变化,并且鉴定出的 METK 拷贝数减少可能作为狗耐药的标志物,与增加的别嘌醇耐药相关的是蛋白质活性降低。